Small Caps, Bitcoin Rally As Traders Await Fed Rate Cut; Treasury Yields, US Dollar Tick Up On Strong Retail Sales: What's Driving Markets Tuesday?
Rhythm Pharma Draws Bullish View at JMP on Opportunity in Rare Genetic Obesities
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
Unpacking the Latest Options Trading Trends in Eli Lilly
BioNTech Raised to Buy at Jefferies on New Cancer Drug
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Ahead of US FOMC Policy Meeting
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
Senseonics Eversense 365 Glucose Monitor Cleared in the U.S.
Sector-wise Weekly ETF Flows - Money Pours Out of Financials and Into Consumer Staples
BeyondSpring Plinabulin, Merck Keytruda Combo Shows Promise in NSCLC
What the Options Market Tells Us About UnitedHealth Group
A Closer Look at 8 Analyst Recommendations For Merck & Co
CG Oncology Surges 7%; Seen Benefitting From J&J Bladder Cancer Asset Data
Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $155 Price Target
Merck & Co Analyst Ratings
Eli Lilly Analyst Ratings
Moderna Was Most Shorted S&P 500 Healthcare Stock in August for Second Consecutive Month
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
Johnson & Johnson Analyst Ratings
Immutep's Efti In Combination With MSD's KEYTRUDA Leads To Efficacy With Favourable Safety In First Line Head And Neck Cancer